Fritextsökning
Innehållstyper
-
She is CSL Behring's new Nordic General Manager
Since the beginning of january, Helena Bragd is the new Nordic General Manager for the biotech company CSL Behring and CEO of CSL Behring AB.
-
Save the dates: ZEISS Quality Innovation Summit, October 22-24
Embark on a journey to the future of metrology.
-
The business coach: “We need to learn from our mistakes”
The past year has been challenging for many biotech companies, with several comapanies facing financial stress and bankruptcy. To understand how entrepreneurs c...
-
100 years of Festo
The spirit of invention is deeply rooted in our corporate culture. Since our foundation, we have been setting benchmarks by developing innovative solutions that...
-
Large study: The benefits and risks of obesity medications
Medications such as Ozempic can reduce the risk of a range of different diseases and health conditions but also increase the risk of others. This is according t...
-
The Top 10 Challenges Facing Laboratories Today
Navigating the Laboratory Automation Landscape
-
Novartis storsatsar på RNA-terapier – köper miljardbolag
Novartis förvärvar amerikanska Avidity Biosciences för 12 miljarder dollar, motsvarande 113 miljarder kronor. Köpet stärker bolagets position inom sällsynta mus...
-
Developing rapid diagnostics for sepsis – “Every hour counts”
Finding the right antibiotic in the right dose – with an ultra-fast analysis method. Gradientech's product solution is currently used in routine diagnostics at ...
-
Astra Zeneca’s asthma drug nears approval for sinus inflammation
Astra Zeneca’s drug Tezspire receives positive opinion from the European Medicines Agency (EMA) for the treatment of chronic rhinosinusitis with nasal polyps.
-
Cost-efficient development of laboratory devices
8 ways to optimise development costs and speed up processes
-
What will be the next big hype after obesity? – An expert panel highlighted their top picks
What will be the next big trend in life science? Everything from Alzheimer’s, Crispr and Omics were highlighted when the issue was debated at this year’s major ...
-
ZEISS receives FDA clearance for INTRABEAM 700
With its new treatment platform for intraoperative radiotherapy, ZEISS is actively shaping the medical innovation of neuro tumor therapy.
-
FDA approves new cystic fibrosis therapy
A new treatment for cystic fibrosis has been approved by the U.S. Food and Drug Administration (FDA).
-
Eli Lilly tecknar miljardavtal med AI-bolag för fetmaforskning
Eli Lilly har tecknat ett mångmiljardavtal med startupen Superluminal Medicines som använder AI för upptäcka och utveckla småmolekylära läkemedel för behandling...
-
Security flaw in Swedish breast cancer screening software – woman passed away
A lack of safeguard in Sectra's software led to a woman with breast cancer receiving an incorrect diagnosis. She later passed away. The software is used in 20 o...
-
Discover Precision: Join ZEISS at the Control Fair in Stuttgart
May 6-9, 2025 in Stuttgart. Hall 9, Booth 9309.
-
Pneumatics Makes a Technological Leap with Piezo
The first high-precision proportional valve terminal VTEP opens up new application areas
-
We desire talent to come here, but are we genuinely welcoming them?
Sweden faces significant challenges in creating a truly inclusive environment that makes international professionals feel welcome, valued, and able to build mea...
-
AI speeds up measurement process
How to inspect coatings ten times faster with a light microscope? The medical technology group Smith+Nephew has been using ZEISS Axio Imager.Z2m since summer 2022.
-
How to avoid measurement inaccuracies due to wear
Expert tip from ZEISS.
-
Life science trends 2025 – Part 1 obesity drugs
More obesity drugs are being launched this year following Novo Nordisk and Eli Lilly's previous successes with GLP-1 drugs. But the next big breakthrough in obe...
-
ZEISS at EMO Hannover 2025
Experience some of the most exciting highlights from our ZEISS product portfolio.
-
Introducing ZEISS arivis Pro 4.2
ZEISS arivis software enhances custom microscopy image analysis.
-
GSK acquires oncology research company
GSK acquires the American biotechnology company Idrx for up to 1.15 billion dollars.
BREAKING